The patent application relates to the use of naringenin in an effective amount for slowing, counteracting and preventing the process offormation of albinotic spots on skin. The patent application also relates to a preparation containing naringenin in an effective amount as the active ingredient and cosmetically acceptable excipients, vehicle and additives, for use in slowing, counteracting and preventing the process formation of albinotic spots on skin and also relates to a method of slowing, counteracting and preventing the process of formation of albinotic spots on skin.

Patent was granted in Poland. Nencki Institute is the co-owner of the applicable rights with Dr Irena Eris (Laboratorium Kosmetyczne Dr Irena Eris Sp. z o. o.). The company is actively using the invention in their 4 lines of products: Pharmaceris H+, Lirene Ideale Pro 45+, Lirene Ideale Pro 55+ and Authority.

For more information contact Technology Transfer Office.